Birchview Capital’s Relmada Therapeutics RLMD Stock Holding History
Bought
Maintained
Sold
Other funds holding RLMD
JT
SCM
VA
SSC
JHC
O
Birchview Capital's RLMD Position: Q2 2026 in Review
Birchview Capital reduced its Relmada Therapeutics (RLMD) stake by 0.31% in Q2 2026, selling an estimated $8.99K and leaving 408,100 shares worth $2.82M. The position accounts for 1.32% of the portfolio, ranked #16.
Birchview Capital first reported a position in RLMD in Q1 2026 and has held it in 2 quarters since. The position peaked at $2.85M in Q1 2026. 126 funds tracked by Wall St. Rank hold RLMD as of Q2 2026.
- Birchview Capital held 408,100 shares of Relmada Therapeutics worth $2.82M as of Q2 2026.
- Birchview Capital sold 1,287 Relmada Therapeutics shares in Q2 2026, an estimated $8.99K.
- Relmada Therapeutics made up 1.32% of Birchview Capital's portfolio in Q2 2026, its #16 holding.
- Birchview Capital first reported a position in Relmada Therapeutics in Q1 2026 and has held it in 2 quarters since.
- Birchview Capital's Relmada Therapeutics position peaked at $2.85M in Q1 2026.
- 126 funds tracked by Wall St. Rank held Relmada Therapeutics as of Q2 2026.
Based on Birchview Capital's 13F filing for Q2 2026, filed 14 Aug 2026.